<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Bone</journal-id><journal-id journal-id-type="iso-abbrev">Bone</journal-id><journal-title-group><journal-title>Bone</journal-title></journal-title-group><issn pub-type="ppub">8756-3282</issn><issn pub-type="epub">1873-2763</issn><publisher><publisher-name>Elsevier Science</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28918311</article-id><article-id pub-id-type="pmc">5871398</article-id><article-id pub-id-type="publisher-id">S8756-3282(17)30340-X</article-id><article-id pub-id-type="doi">10.1016/j.bone.2017.09.004</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Williams</surname><given-names>Eleanor</given-names></name></contrib><contrib contrib-type="author"><name><surname>Bullock</surname><given-names>Alex N.</given-names></name><email>alex.bullock@sgc.ox.ac.uk</email><xref rid="cr0005" ref-type="corresp">&#x0204e;</xref></contrib></contrib-group><aff id="af0005">Structural Genomics Consortium, University of Oxford, Roosevelt Drive, Oxford OX3 7DQ, UK</aff><author-notes><corresp id="cr0005"><label>&#x0204e;</label>Corresponding author. <email>alex.bullock@sgc.ox.ac.uk</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>1</day><month>4</month><year>2018</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.--><pub-date pub-type="ppub"><month>4</month><year>2018</year></pub-date><volume>109</volume><fpage>251</fpage><lpage>258</lpage><history><date date-type="received"><day>6</day><month>7</month><year>2017</year></date><date date-type="rev-recd"><day>10</day><month>9</month><year>2017</year></date><date date-type="accepted"><day>11</day><month>9</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 The Authors</copyright-statement><copyright-year>2017</copyright-year><license license-type="CC BY" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="ab0005"><p>Individuals with the rare developmental disorder fibrodysplasia ossificans progressiva (FOP) experience disabling heterotopic ossification caused by a gain of function mutation in the intracellular region of the BMP type I receptor kinase ALK2, encoded by the gene <italic>ACVR1</italic>. Small molecule BMP type I receptor inhibitors that block this ossification in FOP mouse models have been derived from the pyrazolo[1,5-<italic>a</italic>]pyrimidine scaffold of dorsomorphin. While the first derivative LDN-193189 exhibited pan inhibition of BMP receptors, the more recent compound LDN-212854 has shown increased selectivity for ALK2. Here we solved the crystal structure of ALK2 in complex with LDN-212854 to define how its binding interactions compare to previously reported BMP and TGF&#x003b2; receptor inhibitors. LDN-212854 bound to the kinase hinge region as a typical type I ATP-competitive inhibitor with a single hydrogen bond to ALK2 His286. Specificity arising from the 5-quinoline moiety was associated with a distinct pattern of water-mediated hydrogen bonds involving Lys235 and Glu248 in the inactive conformation favoured by ALK2. The structure of this complex provides a template for the design of future ALK2 inhibitors under development for the treatment of FOP and other related conditions of heterotopic ossification.</p></abstract><abstract abstract-type="graphical" id="ab0010"><title>Graphical abstract</title><p><fig id="f0035" position="anchor"><alt-text id="al0040">Image 1</alt-text><graphic xlink:href="fx1"/></fig></p></abstract><abstract abstract-type="author-highlights" id="ab0015"><title>Highlights</title><p><list list-type="simple" id="l0005"><list-item id="li0005"><label>&#x02022;</label><p id="p0005">We solved a crystal structure of the BMP receptor ALK2 genetically linked to FOP.</p></list-item><list-item id="li0010"><label>&#x02022;</label><p id="p0010">The inhibitor LDN-212854 bound to the ATP-binding pocket of the kinase domain.</p></list-item><list-item id="li0015"><label>&#x02022;</label><p id="p0015">Binding of the inhibitor was supported by water-mediated hydrogen bonds.</p></list-item><list-item id="li0020"><label>&#x02022;</label><p id="p0020">This hydrogen bonding pattern contributes to the inhibitor's selectivity for ALK2.</p></list-item></list></p></abstract><kwd-group id="ks0005"><title>Keywords</title><kwd>BMP</kwd><kwd>Heterotopic ossification</kwd><kwd>Kinase inhibitor</kwd><kwd>Crystal structure</kwd><kwd>Drug</kwd><kwd>Fibrodysplasia ossificans progressiva</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0025">Bone morphogenetic proteins (BMPs) represent the largest subgroup in the TGF&#x003b2; family of extracellular ligands <xref rid="bb0005" ref-type="bibr">[1]</xref>, <xref rid="bb0010" ref-type="bibr">[2]</xref>. Signal transduction by these ligands requires type I and type II transmembrane receptor serine/threonine kinases which form heterotetrameric complexes for ligand interaction. The identity of the ligand determines the specific recruitment of receptors and the downstream signalling <xref rid="bb0015" ref-type="bibr">[3]</xref>. Type I receptors phosphorylate SMAD family transcription factors, whereas type II receptors are required to activate the type I receptors by phosphorylation of their juxtamembrane GS (glycine-serine rich) domain. Type I receptors ALK1/<italic>ACVRL1</italic>, ALK2/<italic>ACVR1</italic>, ALK3/<italic>BMPR1A</italic> and ALK6/<italic>BMPR1B</italic> all participate in BMP signalling and phosphorylate SMAD1/5/8. In contrast, the Activin type I receptors ALK4/<italic>ACVR1B</italic> and ALK7/<italic>ACVR1C</italic> and the TGF&#x003b2; type I receptor (ALK5/<italic>TGFBRI</italic>) all primarily signal through SMAD2/3. In addition, the receptor signalling complexes can activate a variety of non-canonical pathways, including the p38 MAPK and phosphoinositide 3-kinase (PI3K) signalling cascades. Characterisation of these receptors and their signalling pathways has been pivotal to our understanding of the effects of BMP signalling in processes such as embryonic patterning, tissue differentiation and homeostasis <xref rid="bb0020" ref-type="bibr">[4]</xref>, <xref rid="bb0025" ref-type="bibr">[5]</xref>, <xref rid="bb0030" ref-type="bibr">[6]</xref>.</p><p id="p0030">The importance of BMP signalling is evident from the many disease conditions that are genetically linked to the dysregulation of these pathways <xref rid="bb0030" ref-type="bibr">[6]</xref>, <xref rid="bb0035" ref-type="bibr">[7]</xref>. Most commonly these involve loss of function mutations, as exemplified by <italic>ACVRL1</italic> and <italic>BMPR1A</italic> mutations which predispose to hereditary haemorrhagic telangiectasia <xref rid="bb0040" ref-type="bibr">[8]</xref> and juvenile polyposis syndrome <xref rid="bb0045" ref-type="bibr">[9]</xref>, <xref rid="bb0050" ref-type="bibr">[10]</xref>, respectively. By contrast, fibrodysplasia ossificans progressiva (FOP) is a rare monogenic condition in which a gain of function germline mutation in <italic>ACVR1</italic> leads to increased signalling through ALK2 in response to BMP ligands as well as neofunction in response to Activin A and the consequent formation of heterotopic bone in muscle and connective tissue <xref rid="bb0055" ref-type="bibr">[11]</xref>, <xref rid="bb0060" ref-type="bibr">[12]</xref>. Similar somatic mutations in <italic>ACVR1</italic> are also observed in 25% of cases of diffuse intrinsic pontine glioma (DIPG), a rare childhood brain tumour <xref rid="bb0065" ref-type="bibr">[13]</xref>. BMP signalling has also been linked to other human cancers. For example, BMP2 can promote the expansion of ovarian cancer stem cells <xref rid="bb0070" ref-type="bibr">[14]</xref>, while BMP6 overexpression is associated with prostate cancer skeletal metastases <xref rid="bb0075" ref-type="bibr">[15]</xref>, <xref rid="bb0080" ref-type="bibr">[16]</xref>. Notably, BMP type I receptor inhibitors have demonstrated promising effects in DIPG patient cell lines <xref rid="bb0085" ref-type="bibr">[17]</xref>, as well as a number of other cancer models <xref rid="bb0090" ref-type="bibr">[18]</xref>, <xref rid="bb0095" ref-type="bibr">[19]</xref>, <xref rid="bb0100" ref-type="bibr">[20]</xref>, <xref rid="bb0105" ref-type="bibr">[21]</xref>, <xref rid="bb0110" ref-type="bibr">[22]</xref>, <xref rid="bb0115" ref-type="bibr">[23]</xref>, <xref rid="bb0120" ref-type="bibr">[24]</xref>, <xref rid="bb0125" ref-type="bibr">[25]</xref>. BMP signalling has also been identified as a promising therapeutic target to normalize hepcidin expression in chronic anaemia of inflammation <xref rid="bb0130" ref-type="bibr">[26]</xref>, <xref rid="bb0135" ref-type="bibr">[27]</xref>.</p><p id="p0035">These data have stimulated interest in the development of small molecule BMP type I receptor inhibitors both as therapeutic agents and as chemical tools to probe cellular signalling mechanisms <xref rid="bb0035" ref-type="bibr">[7]</xref>, <xref rid="bb0140" ref-type="bibr">[28]</xref>. Dorsomorphin was discovered as the first small molecule BMP receptor inhibitor using a phenotypic screen to identify compounds capable of inducing the dorsalization of zebrafish embryos, as observed for the mutant BMP receptor <italic>lost-a-fin</italic>
<xref rid="bb0130" ref-type="bibr">[26]</xref>. A crystal structure of the human orthologue ALK2 confirmed the direct binding of dorsomorphin to the ATP-binding pocket of the receptor's intracellular kinase domain <xref rid="bb0145" ref-type="bibr">[29]</xref>. Further development of the pyrazolo[1,5-<italic>a</italic>]pyrimidine-containing scaffold has subsequently produced a series of derivative compounds, including LDN-193189 <xref rid="bb0150" ref-type="bibr">[30]</xref>, DMH1 <xref rid="bb0155" ref-type="bibr">[31]</xref>, VU465350 <xref rid="bb0160" ref-type="bibr">[32]</xref>, and LDN-212854 <xref rid="bb0165" ref-type="bibr">[33]</xref> (<xref rid="f0005" ref-type="fig">Fig. 1</xref>a). LDN-193189 was selected for its improved potency and pharmacokinetic properties <xref rid="bb0150" ref-type="bibr">[30]</xref>, which have enabled its use in animal models of heterotopic ossification <xref rid="bb0170" ref-type="bibr">[34]</xref>, vascular calcification <xref rid="bb0175" ref-type="bibr">[35]</xref> and anaemia of inflammation <xref rid="bb0135" ref-type="bibr">[27]</xref>. DMH1 was identified from further zebrafish screening to reduce off-target activity against the VEGF pathway <xref rid="bb0155" ref-type="bibr">[31]</xref>. Finally, VU465350 and LDN-212854 were recently reported as inhibitors harboring increased subfamily selectivity for ALK3 and ALK2, respectively <xref rid="bb0160" ref-type="bibr">[32]</xref>, <xref rid="bb0165" ref-type="bibr">[33]</xref>. In addition, a second series of pyridine-based small molecule BMP type I receptor inhibitors was identified from a biochemical screen against the purified ALK2 kinase domain (<xref rid="f0005" ref-type="fig">Fig. 1</xref>b). The initial screening hit K02288 showed remarkable selectivity for BMP receptors over a panel of some 250 human kinases <xref rid="bb0180" ref-type="bibr">[36]</xref>. Subsequent work yielded the compound LDN-214117, which displayed superior activity in cells, as well as enhanced selectivity for ALK2 over ALK5 <xref rid="bb0185" ref-type="bibr">[37]</xref>.<fig id="f0005"><label>Fig. 1</label><caption><p>Chemical scaffolds of selected BMP type I receptor inhibitors. (A) Selected inhibitors derived from the core pyrazolo[1,5-<italic>a</italic>]pyrimidine scaffold of dorsomorphin. (B) Inhibitors based on an alternative pyridine-based scaffold. IC<sub>50</sub> data are those reviewed by Hopkins <xref rid="bb0190" ref-type="bibr">[38]</xref> except the data for LDN-214117 which are taken from Mohedas et al. <xref rid="bb0185" ref-type="bibr">[37]</xref>.</p></caption><alt-text id="al0005">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig></p><p id="p0040">The compound LDN-212854 is of particular interest for the development of inhibitors against heterotopic ossification. It has demonstrated notable efficacy in two different mouse models, including one using an inducible constitutively-active <italic>ACVR1</italic><sup>Q207D</sup> transgene <xref rid="bb0165" ref-type="bibr">[33]</xref> and another harboring an <italic>Acvr1</italic><sup>R206H</sup> knock-in allele that more faithfully recapitulates human FOP <xref rid="bb0195" ref-type="bibr">[39]</xref>. LDN-212854 was developed from LDN-193189 through the substitution of a 4-quinoline moiety for a 5-quinoline (<xref rid="f0005" ref-type="fig">Fig. 1</xref>a) <xref rid="bb0165" ref-type="bibr">[33]</xref>. Remarkably, this simple change increased the compound's selectivity for ALK2 over ALK3 from 21-fold (LDN-193189) to 66-fold (LDN-212854). In addition, the selectivity for ALK2 over ALK5 was increased from 175-fold to over 9000-fold <xref rid="bb0165" ref-type="bibr">[33]</xref>. Thus, the ALK2 bias of LDN-212854 is ideally suited to counter the <italic>ACVR1</italic><sup>R206H</sup> mutation that underlies FOP. Here we determined the crystal structure of ALK2 in complex with LDN-212854 revealing subtle differences in its binding compared to LDN-193189.</p></sec><sec id="s0010"><label>2</label><title>Materials and methods</title><sec id="s0015"><label>2.1</label><title>Protein expression and purification</title><p id="p0045">The recombinant ALK2 kinase domain was prepared with a Q207D mutation as previously described <xref rid="bb0180" ref-type="bibr">[36]</xref>. Briefly, ALK2 residues 201&#x02013;499 were cloned into transfer vector pFB-LIC-Bse and baculovirus prepared in DH10Bac cells. Baculoviral expression was performed in Sf9 insect cells grown at 27&#x000a0;&#x000b0;C. Some 48&#x000a0;h post-infection, cells were harvested and lysed using ultrasonication. ALK2 protein was purified sequentially by nickel affinity and size-exclusion chromatography. The eluted protein was stored at &#x02212;&#x000a0;80&#x000a0;&#x000b0;C buffered in 50&#x000a0;mM HEPES, pH&#x000a0;7.5, 300&#x000a0;mM NaCl, 2&#x000a0;mM DTT, 50&#x000a0;mM arginine, 50&#x000a0;mM glutamate. The N-terminal hexahistidine tag used for purification was cleaved using tobacco etch virus (TEV) protease.</p></sec><sec id="s0020"><label>2.2</label><title>Crystallization</title><p id="p0050">Crystallization was achieved at 4&#x000a0;&#x000b0;C using the sitting-drop vapor diffusion method. ALK2 was preincubated with 1&#x000a0;mM LDN-212854 at a protein concentration of 13.6&#x000a0;mg/mL and crystallized using a precipitant containing 18% PEG8000, 0.2&#x000a0;M calcium acetate, 0.1&#x000a0;M cacodylate pH&#x000a0;6.5. Viable crystals were obtained when the protein solution was mixed with the reservoir solution at 2:1 volume ratio. Crystals were cryoprotected with mother liquor plus 25% ethylene glycol, prior to vitrification in liquid nitrogen.</p></sec><sec id="s0025"><label>2.3</label><title>Data collection</title><p id="p0055">Diffraction data were collected at the Diamond Light Source, station I03 using monochromatic radiation at wavelength 0.97625&#x000a0;&#x000c5;.</p></sec><sec id="s0030"><label>2.4</label><title>Phasing, model building, refinement, and validation</title><p id="p0060">Data were processed with MOSFLM <xref rid="bb0200" ref-type="bibr">[40]</xref> and subsequently scaled using the program AIMLESS from the CCP4 suite <xref rid="bb0205" ref-type="bibr">[41]</xref>. Initial phases were obtained by molecular replacement using the program PHASER <xref rid="bb0210" ref-type="bibr">[42]</xref> and the structure of ALK2 (PDB ID <ext-link ext-link-type="uri" xlink:href="pdb:3H9R" id="ir0015">3H9R</ext-link>) as a search model. The resulting structure solution was refined using REFMAC5 from the CCP4 suite <xref rid="bb0215" ref-type="bibr">[43]</xref> and manually rebuilt with COOT <xref rid="bb0220" ref-type="bibr">[44]</xref>. Appropriate TLS restrained refinement using the tls tensor files calculated from the program TLSMD <xref rid="bb0225" ref-type="bibr">[45]</xref> was applied at the final round of refinement. The complete structure was verified for geometric correctness with MolProbity <xref rid="bb0230" ref-type="bibr">[46]</xref>. Data collection and refinement statistics are shown in <xref rid="t0005" ref-type="table">Table 1</xref>.<table-wrap id="t0005" position="float"><label>Table 1</label><caption><p>Data collection and refinement statistics (molecular replacement).</p></caption><alt-text id="al0035">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th/><th>ALK2-LDN-212854 (PDB ID 5OXG)</th></tr></thead><tbody><tr><td><italic>Data collection</italic></td><td/></tr><tr><td>Space group</td><td><italic>I</italic>121</td></tr><tr><td>Cell dimensions</td><td/></tr><tr><td>&#x000a0;<italic>a</italic>, <italic>b</italic>, <italic>c</italic> (&#x000c5;)</td><td>85.9, 102.2, 177.3</td></tr><tr><td>&#x000a0;&#x003b1;, &#x003b2;, &#x003b3; (&#x000b0;)</td><td>90.0, 94.0, 90.0,</td></tr><tr><td>Resolution (&#x000c5;)<xref rid="tf0005" ref-type="table-fn">a</xref></td><td>88.49&#x02013;1.73 (1.80&#x02013;1.73)</td></tr><tr><td><italic>R</italic><sub>merge</sub><xref rid="tf0005" ref-type="table-fn">a</xref></td><td>0.0681 (1.284)</td></tr><tr><td><italic>I</italic>/&#x003c3;<italic>I</italic><xref rid="tf0005" ref-type="table-fn">a</xref></td><td>4.91 (0.56)</td></tr><tr><td>Completeness (%)<xref rid="tf0005" ref-type="table-fn">a</xref></td><td>99.30 (97.95)</td></tr><tr><td>Redundancy<xref rid="tf0005" ref-type="table-fn">a</xref></td><td>1.9 (1.8)</td></tr><tr><td><italic>Refinement</italic></td><td/></tr><tr><td>Resolution (&#x000c5;)</td><td>2.13</td></tr><tr><td>No. reflections<xref rid="tf0005" ref-type="table-fn">a</xref></td><td>293,366 (27506)</td></tr><tr><td><italic>R</italic><sub>work</sub>/<italic>R</italic><sub>free</sub></td><td>0.22/0.25</td></tr><tr><td>No. atoms</td><td>9810</td></tr><tr><td>&#x000a0;Protein</td><td>9326</td></tr><tr><td>&#x000a0;Ligand/ion</td><td>139</td></tr><tr><td>&#x000a0;Water</td><td>345</td></tr><tr><td>B-factors</td><td>46.00</td></tr><tr><td>&#x000a0;Protein</td><td>45.90</td></tr><tr><td>&#x000a0;Ligand/ion</td><td>47.10</td></tr><tr><td>&#x000a0;Water</td><td>46.70</td></tr><tr><td>R.m.s deviations</td><td/></tr><tr><td>&#x000a0;Bond lengths (&#x000c5;)</td><td>0.012</td></tr><tr><td>&#x000a0;Bond angles (&#x000b0;)</td><td>1.49</td></tr></tbody></table><table-wrap-foot><fn><p>Data from a single crystal.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tf0005"><label>a</label><p id="np0005">Highest resolution shell is shown in parenthesis.</p></fn></table-wrap-foot></table-wrap></p></sec></sec><sec id="s0035"><label>3</label><title>Results and discussion</title><p id="p0065">To date, all small molecule BMP receptor inhibitors have been targeted to the ATP-binding pocket located within the intracellular kinase domain of the receptors. While this region is highly conserved across the BMP receptor family, crystallographic studies can reveal small sequence and conformational differences that may be exploited for the design of inhibitor potency and selectivity <xref rid="bb0145" ref-type="bibr">[29]</xref>, <xref rid="bb0180" ref-type="bibr">[36]</xref>, <xref rid="bb0185" ref-type="bibr">[37]</xref>, <xref rid="bb0235" ref-type="bibr">[47]</xref>, <xref rid="bb0240" ref-type="bibr">[48]</xref>, <xref rid="bb0245" ref-type="bibr">[49]</xref>.</p><sec id="s0040"><label>3.1</label><title>Structure determination of the ALK2-LDN-212854 complex</title><p id="p0070">To facilitate structural studies with LDN-212854, we recombinantly expressed the human ALK2 kinase domain in Sf9 insect cells and purified the resulting protein to homogeneity using Ni-affinity and size exclusion chromatography. This protein construct lacks the more flexible GS domain region and has been found to be highly amenable to crystallization. When mixed together, the ALK2-LDN-212854 complex crystallized in sitting drops in space group <italic>I</italic>121 and yielded excellent diffraction allowing structure refinement at 1.73&#x000a0;&#x000c5; resolution (see <xref rid="t0005" ref-type="table">Table 1</xref> for diffraction data collection and refinement statistics). Four protein-inhibitor complexes were observed in the asymmetric unit with no significant structural differences.</p></sec><sec id="s0045"><label>3.2</label><title>ALK2 exhibits an inactive kinase conformation</title><p id="p0075">The structure of the ALK2 kinase domain in complex with LDN-212854 was observed to adopt an inactive conformation (<xref rid="f0010" ref-type="fig">Fig. 2</xref>) similar to the more complete structure of the ALK2 GS and kinase domains bound to FKBP12 <xref rid="bb0145" ref-type="bibr">[29]</xref>. In this shared inhibitory conformation there is close packing of the kinase N and C-lobes creating strong interactions for the inhibitor bound in the central ATP-binding pocket. However, at the solvent-exposed entrance of the active site the binding of ATP and substrate would be sterically occluded by the inward folding of the activation segment <xref rid="bb0145" ref-type="bibr">[29]</xref>. Importantly, FOP-causative mutations such as R375P disrupt this inhibitory packing and therefore sensitize the mutant ALK2 receptor to activation <xref rid="bb0145" ref-type="bibr">[29]</xref>.<fig id="f0010"><label>Fig. 2</label><caption><p>Structure of ALK2 bound to LDN-212854. (A) Chemical structure of LDN-212854 highlighting the piperazine and 5-quinoline moieties. (B) (Left) Ribbon diagram showing the structure of the ALK2 kinase domain. The activation segment (pink) adopts an inactive conformation that inserts into the front of the ATP-binding pocket and would block ATP binding. (Right inset) The compound LDN-212854 binds to the hinge region which connects the N and C-terminal lobes of the kinase domain. The N-1 nitrogen from the core pyrazolo[1,5-<italic>a</italic>]pyrimidine group forms a single hydrogen bond (dashed line) to the backbone amide of H286.</p></caption><alt-text id="al0010">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig></p></sec><sec id="s0050"><label>3.3</label><title>Conserved binding mode of LDN-212854</title><p id="p0080">LDN-212854 contains the same core pyrazolo[1,5-<italic>a</italic>]pyrimidine scaffold as LDN-193189, which has been co-crystallized previously with ALK2 <xref rid="bb0180" ref-type="bibr">[36]</xref>. As expected, this group binds to the hinge region which connects the N and C-lobes of the kinase domain (<xref rid="f0010" ref-type="fig">Fig. 2</xref>). Here, a single hydrogen bond is observed between the N-1 nitrogen of the pyrazolo[1,5-<italic>a</italic>]pyrimidine moiety and the backbone nitrogen of His286 (<xref rid="f0010" ref-type="fig">Fig. 2</xref>). The pendant phenyl ring is also similarly packed below the &#x003b2;1 strand where its hydrophobic interactions include van der Waals contacts with Val214 (<xref rid="f0010" ref-type="fig">Fig. 2</xref>). The piperazine ring is largely solvent exposed at the front of the ATP-binding pocket (<xref rid="f0010" ref-type="fig">Fig. 2</xref>) and therefore suitable for any future chemical modifications. Most importantly, the central pyrazolo[1,5-<italic>a</italic>]pyrimidine moiety orients the 5-quinoline group to the back pocket where it packs below Val222 (<xref rid="f0010" ref-type="fig">Fig. 2</xref>). This region of the ATP-binding pocket presents a richly hydrophobic environment including Val222, Ala232, Leu263, Leu281, Leu343 and Ala353. The large 5-quinoline group exploits this back pocket region similarly to the 4-quinoline of LDN-193189.</p></sec><sec id="s0055"><label>3.4</label><title>Differences in the binding of LDN-212854 and LDN-193189</title><p id="p0085">Direct comparison of the binding modes of LDN-212854 and LDN-193189 is critical to provide a rational for their different selectivity (<xref rid="f0005" ref-type="fig">Fig. 1</xref>, <xref rid="f0015" ref-type="fig">Fig. 3</xref>). The overall binding poises of these molecules are almost identical. Moreover, the conformations of all side chains within the ATP-binding pocket are unchanged. Instead, differences are observed in the water networks surrounding the quinoline nitrogens (<xref rid="f0015" ref-type="fig">Fig. 3</xref>). In the inactive ALK2 conformation the catalytically important salt bridge between Lys235 (&#x003b2;3 strand) and Glu248 (&#x003b1;C) is broken and these side chains are free for interaction with inhibitors. The nitrogen of the 5-quinoline of LDN-212854 appears optimally positioned to form a water-mediated hydrogen bond that bifurcates to contact both Lys235 and Glu248 (<xref rid="f0015" ref-type="fig">Fig. 3</xref>A). The position of Lys235 is further stabilized by another water-mediated hydrogen bond to Asp241 also located within the &#x003b1;C helix (<xref rid="f0015" ref-type="fig">Fig. 3</xref>A).<fig id="f0015"><label>Fig. 3</label><caption><p>Water-mediated hydrogen bond interactions of selected kinase inhibitor complexes. (A) Close up of the ATP-binding pocket of ALK2 viewed from the side of the &#x003b1;C helix. Hydrogen bonds (dashed lines) are shown to water molecules (single blue spheres) with distances. The 5-quinoline of LDN-212854 forms water-mediated hydrogen bonds with K235 and E248. Other water-mediated interactions are similarly labelled. (B) The 4-quinoline of LDN-193189 forms a water-mediated hydrogen bond to E248, but is too distant (3.54&#x000a0;&#x000c5;) to contact K235. (C) The apo structure of ALK5 (PDB <ext-link ext-link-type="uri" xlink:href="pdb:5E8S" id="ir0005">5E8S</ext-link>) also shows a water network in this vicinity, but the equivalent residues K232 and E245 side chains are sufficiently close to form a direct salt bridge. (D) An inhibitor bound structure of ALK5 (PDB <ext-link ext-link-type="uri" xlink:href="pdb:5USQ" id="ir0010">5USQ</ext-link>) shows a water-mediated hydrogen bond from the inhibitor's pyridine moiety to E245 in the &#x003b1;C helix.</p></caption><alt-text id="al0015">Fig. 3</alt-text><graphic xlink:href="gr3"/></fig></p><p id="p0090">By comparison, the 4-quinoline of LDN-193189 places the nitrogen deeper into the back pocket of the ATP-binding site (as also found in the 4-pyridine of dorsomorphin, <xref rid="f0005" ref-type="fig">Fig. 1</xref>). This nitrogen also forms a water-mediated hydrogen bond to Glu248 (<xref rid="f0015" ref-type="fig">Fig. 3</xref>B). However, the equivalent water is shifted some 1.54&#x000a0;&#x000c5; further back into the ATP-binding pocket to better match the 4-quinoline. As a result, this water is moved beyond the normal hydrogen bond distance from Ly235 (3.54&#x000a0;&#x000c5;, <xref rid="f0015" ref-type="fig">Fig. 3</xref>B). Thus, the 5-quinoline of LDN-212854 appears particularly favourable for establishing a larger network of water-mediated hydrogen bonding in ALK2.</p></sec><sec id="s0060"><label>3.5</label><title>Differences in the inhibitor binding of ALK2 and ALK5</title><p id="p0095">We also wanted to compare structures of ALK2 and ALK5 to explore whether the observed water network might additionally contribute to the far weaker binding of LDN-212854 to ALK5 relative to other small molecule BMP type I receptor inhibitors. This is germane given the high sequence conservation between ALK2 and ALK5 in the relevant back pocket region. Unfortunately, there are no available ALK5 structures that are directly comparable with a bound small molecule BMP type I receptor inhibitor. Instead, we analyzed a range of representative ALK5 structures including the apo state (PDB <ext-link ext-link-type="uri" xlink:href="pdb:5E8S" id="ir0020">5E8S</ext-link>
<xref rid="bb0250" ref-type="bibr">[50]</xref>, <xref rid="f0015" ref-type="fig">Fig. 3</xref>C) and one bound to a pyrazolo[4,3-<italic>b</italic>]pyridine-based ligand (PDB <ext-link ext-link-type="uri" xlink:href="pdb:5USQ" id="ir0025">5USQ</ext-link>
<xref rid="bb0255" ref-type="bibr">[51]</xref>, <xref rid="f0015" ref-type="fig">Fig. 3</xref>D). Most notably, structures of the isolated kinase domain of ALK5 show a greater tendency to adopt an active conformation as evidenced by the correct positioning of the &#x003b1;C helix, which enables the Lys232-Glu245 salt bridge (<xref rid="f0015" ref-type="fig">Fig. 3</xref>C and D). Thus, in these ALK5 structures water is excluded directly between these side chains and instead other water-mediated hydrogen bond interactions are observed, such as between Ser241 and Glu245 (<xref rid="f0015" ref-type="fig">Fig. 3</xref>C).</p><p id="p0100">Whereas different ALK2 structures closely match (<xref rid="f0020" ref-type="fig">Fig. 4</xref>A and B), the superposition of ALK2 and ALK5 structures reveals shifts in conformation and side chain position that significantly change the character of the back pocket around the site of the 5-quinoline of LDN-212854 (<xref rid="f0020" ref-type="fig">Fig. 4</xref>C and D). The bound ligand in the ALK5 structure corresponding to PDB <ext-link ext-link-type="uri" xlink:href="pdb:5USQ" id="ir0030">5USQ</ext-link> includes a pyridine moiety with a nitrogen atom positioned identically to that of the nitrogen in the 4-quinoline of LDN-193189 (<xref rid="f0020" ref-type="fig">Fig. 4</xref>D). In the ALK5 structure, this nitrogen forms a comparable water-mediated hydrogen bond to Glu245 in the &#x003b1;C helix, as well as extra contacts to the side chain of Tyr249 and to the backbone amide of Asp351 (<xref rid="f0020" ref-type="fig">Fig. 4</xref>D). Thus, this nitrogen position appears particularly favourable for the ALK5 structure, although extending the pyridine into a quinoline would necessarily alter the position of the Asp351 side chain to avoid a steric clash (<xref rid="f0020" ref-type="fig">Fig. 4</xref>D). The binding of LDN-212854 to ALK5 would necessitate a change in this water network and therefore likely destabilize the current conformation. For example, a new water position bridging between Glu245 and the 5-quinoline would likely disrupt the former water-mediated interactions with Tyr249 and Asp351.<fig id="f0020"><label>Fig. 4</label><caption><p>Comparison of inhibitor interactions in ALK2 and ALK5. (A) Superposition shows that the overall binding poises of LDN-193189 (orange) and LDN-212854 (blue) in ALK2 are closely conserved, but there are subtle changes in the surrounding water networks. (B) Rotated view showing a close up of the quinoline interaction. The binding of the 4-quinoline of LDN-193189 (orange) includes a key water-mediated hydrogen bond to E248. An equivalent water in the LDN-212854 co-structure (blue) is shifted slightly allowing interaction with both E248 and K235. (C) Superposition of ALK2 (blue) and ALK5 (purple) shows a conformational change that alters the position of key side chains. Waters observed in the ALK2 and ALK5 co-structures, colored blue and purple, respectively, are also positioned differently. (D) Rotated view as in panel B. Superposition shows a pyridine nitrogen in the ALK5 inhibitor that is positioned equivalently to the 4-quinoline nitrogen of LDN-193189 bound to ALK2. In the ALK5 structure (purple), this nitrogen forms a comparable water-mediated hydrogen bond to Glu245 in the &#x003b1;C helix, as well as an extra contact to the side chain of Y249. By comparison, the water bound to LDN-212854 in the ALK2 structure is shifted towards the front of the ATP-binding pocket.</p></caption><alt-text id="al0020">Fig. 4</alt-text><graphic xlink:href="gr4"/></fig></p></sec></sec><sec id="s0065"><label>4</label><title>Conclusions</title><p id="p0105">The development of small molecule kinase inhibitors targeted specifically to BMP or TGF&#x003b2; receptors has provided valuable reagents to interrogate these signalling cascades in biology <xref rid="bb0035" ref-type="bibr">[7]</xref>, <xref rid="bb0140" ref-type="bibr">[28]</xref>. Derivatives of the pyrazolo[1,5-<italic>a</italic>]pyrimidine scaffold have proven particularly successful for the development of small molecule BMP type I receptor inhibitors, exploiting the R1 and R2 positions shown in <xref rid="f0025" ref-type="fig">Fig. 5</xref> for potency, selectivity and pharmacokinetic properties. Given the variety of inhibitors now available, it is important that the most appropriate inhibitor is selected for any specific assay. LDN-193189 is suitable as a pan-BMP type I receptor inhibitor, whereas LDN-212854 is recommended for experiments specifically investigating the function of ALK2. Its inhibitory activity is highest against ligands such as BMP6 and BMP7 which favour ALK2, but decreased against ligands such as BMP2 and BMP4 which favour ALK3 <xref rid="bb0165" ref-type="bibr">[33]</xref>. Thus, careful titration of these two inhibitor molecules can enable specific insights into receptor utilization <xref rid="bb0165" ref-type="bibr">[33]</xref>.<fig id="f0025"><label>Fig. 5</label><caption><p>Structure-activity relationship for small molecule BMP type I receptor inhibitors. The pyrazolo[1,5-<italic>a</italic>]pyrimidine scaffold has been modified at the R1 and R2 positions to derive changes in potency, selectivity and pharmacokinetics.</p></caption><alt-text id="al0025">Fig. 5</alt-text><graphic xlink:href="gr5"/></fig></p><p id="p0110">Small molecule inhibitors targeting ALK5 have demonstrated dose limiting cardiac toxicity in the clinic <xref rid="bb0260" ref-type="bibr">[52]</xref>. Efforts to derive ALK2-selective inhibitors for therapeutic application have therefore also aimed to minimize any off-target ALK5 interaction <xref rid="bb0165" ref-type="bibr">[33]</xref>, <xref rid="bb0180" ref-type="bibr">[36]</xref>, <xref rid="bb0185" ref-type="bibr">[37]</xref>. Much of this work has been directed towards the rare congenital syndrome FOP, which is strictly linked to gain of function mutations in the BMP type I receptor ALK2 <xref rid="bb0055" ref-type="bibr">[11]</xref>. All patients with FOP experience episodes of heterotopic ossification in muscle, tendons and ligament that progressively restrict joint movement, such that most individuals are confined to a wheelchair by their third decade of life. The clinical challenge presented by FOP is notably distinct from other disabling pathologies such as Duchenne Muscular Dystrophy (DMD), which is associated with loss of function mutations in the dystrophin gene <italic>DMD</italic>
<xref rid="bb0265" ref-type="bibr">[53]</xref>. In DMD, a drug restoring 10% of dystrophin function may offer significant benefit for a patient's quality of life and muscle function. By contrast, a drug reducing heterotopic ossification by 10% is expected to offer little meaningful impact for FOP patients and a 90% effect or more may be required (<xref rid="f0030" ref-type="fig">Fig. 6</xref>). Thus, potency and selectivity will both be critical parameters for the therapeutic index of any future ALK2 inhibitors entering into clinic trials.<fig id="f0030"><label>Fig. 6</label><caption><p>Schematic comparing the clinical requirements of drugs targeting diseases with loss and gain of function mutations, respectively.</p></caption><alt-text id="al0030">Fig. 6</alt-text><graphic xlink:href="gr6"/></fig></p><p id="p0115">In summary, the inactive conformation of the ALK2 kinase appears to be well suited to the inhibitor scaffold of LDN-212854 and supports a rich network of water-mediated hydrogen bonds. The structure of this complex provides a template for the design of future analogues as well as other chemical series that may exploit this water network to achieve similar levels of potency and selectivity.</p></sec><sec id="s0070"><title>Conflicts of interest</title><p id="p0120">None.</p></sec></body><back><ref-list id="bi0005"><title>References</title><ref id="bb0005"><label>1</label><element-citation publication-type="journal" id="rf0005"><person-group person-group-type="author"><name><surname>Schmierer</surname><given-names>B.</given-names></name><name><surname>Hill</surname><given-names>C.S.</given-names></name></person-group><article-title>TGF beta-SMAD signal transduction: molecular specificity and functional flexibility</article-title><source>Nat. Rev. Mol. Cell Biol.</source><volume>8</volume><issue>12</issue><year>2007</year><fpage>970</fpage><lpage>982</lpage><pub-id pub-id-type="pmid">18000526</pub-id></element-citation></ref><ref id="bb0010"><label>2</label><element-citation publication-type="journal" id="rf0010"><person-group person-group-type="author"><name><surname>Budi</surname><given-names>E.H.</given-names></name><name><surname>Duan</surname><given-names>D.</given-names></name><name><surname>Derynck</surname><given-names>R.</given-names></name></person-group><article-title>Transforming growth factor-beta receptors and Smads: regulatory complexity and functional versatility</article-title><source>Trends Cell Biol.</source><year>2017</year></element-citation></ref><ref id="bb0015"><label>3</label><element-citation publication-type="journal" id="rf0015"><person-group person-group-type="author"><name><surname>Yadin</surname><given-names>D.</given-names></name><name><surname>Knaus</surname><given-names>P.</given-names></name><name><surname>Mueller</surname><given-names>T.D.</given-names></name></person-group><article-title>Structural insights into BMP receptors: specificity, activation and inhibition</article-title><source>Cytokine Growth Factor Rev.</source><volume>27</volume><year>2016</year><fpage>13</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">26690041</pub-id></element-citation></ref><ref id="bb0020"><label>4</label><element-citation publication-type="journal" id="rf0020"><person-group person-group-type="author"><name><surname>Salazar</surname><given-names>V.S.</given-names></name><name><surname>Gamer</surname><given-names>L.W.</given-names></name><name><surname>Rosen</surname><given-names>V.</given-names></name></person-group><article-title>BMP signalling in skeletal development, disease and repair</article-title><source>Nat. Rev. Endocrinol.</source><volume>12</volume><issue>4</issue><year>2016</year><fpage>203</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">26893264</pub-id></element-citation></ref><ref id="bb0025"><label>5</label><element-citation publication-type="journal" id="rf0025"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>M.Y.</given-names></name><name><surname>Hill</surname><given-names>C.S.</given-names></name></person-group><article-title>TGF-beta superfamily signaling in embryonic development and homeostasis</article-title><source>Dev. Cell</source><volume>16</volume><issue>3</issue><year>2009</year><fpage>329</fpage><lpage>343</lpage><pub-id pub-id-type="pmid">19289080</pub-id></element-citation></ref><ref id="bb0030"><label>6</label><element-citation publication-type="journal" id="rf0030"><person-group person-group-type="author"><name><surname>Waite</surname><given-names>K.A.</given-names></name><name><surname>Eng</surname><given-names>C.</given-names></name></person-group><article-title>From developmental disorder to heritable cancer: it's all in the BMP/TGF-[beta] family</article-title><source>Nat. Rev. Genet.</source><volume>4</volume><issue>10</issue><year>2003</year><fpage>763</fpage><lpage>773</lpage><pub-id pub-id-type="pmid">14526373</pub-id></element-citation></ref><ref id="bb0035"><label>7</label><element-citation publication-type="journal" id="rf0035"><person-group person-group-type="author"><name><surname>Hong</surname><given-names>C.C.</given-names></name><name><surname>Yu</surname><given-names>P.B.</given-names></name></person-group><article-title>Applications of small molecule BMP inhibitors in physiology and disease</article-title><source>Cytokine Growth Factor Rev.</source><volume>20</volume><issue>5&#x02013;6</issue><year>2009</year><fpage>409</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">19914855</pub-id></element-citation></ref><ref id="bb0040"><label>8</label><element-citation publication-type="journal" id="rf0040"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>D.W.</given-names></name><name><surname>Berg</surname><given-names>J.N.</given-names></name><name><surname>Baldwin</surname><given-names>M.A.</given-names></name><name><surname>Gallione</surname><given-names>C.J.</given-names></name><name><surname>Marondel</surname><given-names>I.</given-names></name><name><surname>Yoon</surname><given-names>S.J.</given-names></name><name><surname>Stenzel</surname><given-names>T.T.</given-names></name><name><surname>Speer</surname><given-names>M.</given-names></name><name><surname>Pericak-Vance</surname><given-names>M.A.</given-names></name><name><surname>Diamond</surname><given-names>A.</given-names></name><name><surname>Guttmacher</surname><given-names>A.E.</given-names></name><name><surname>Jackson</surname><given-names>C.E.</given-names></name><name><surname>Attisano</surname><given-names>L.</given-names></name><name><surname>Kucherlapati</surname><given-names>R.</given-names></name><name><surname>Porteous</surname><given-names>M.E.M.</given-names></name><name><surname>Marchuk</surname><given-names>D.A.</given-names></name></person-group><article-title>Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2</article-title><source>Nat. Genet.</source><volume>13</volume><issue>2</issue><year>1996</year><fpage>189</fpage><lpage>195</lpage><pub-id pub-id-type="pmid">8640225</pub-id></element-citation></ref><ref id="bb0045"><label>9</label><element-citation publication-type="journal" id="rf0045"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>X.-P.</given-names></name><name><surname>Woodford-Richens</surname><given-names>K.</given-names></name><name><surname>Lehtonen</surname><given-names>R.</given-names></name><name><surname>Kurose</surname><given-names>K.</given-names></name><name><surname>Aldred</surname><given-names>M.</given-names></name><name><surname>Hampel</surname><given-names>H.</given-names></name><name><surname>Launonen</surname><given-names>V.</given-names></name><name><surname>Virta</surname><given-names>S.</given-names></name><name><surname>Pilarski</surname><given-names>R.</given-names></name><name><surname>Salovaara</surname><given-names>R.</given-names></name><name><surname>Bodmer</surname><given-names>W.F.</given-names></name><name><surname>Conrad</surname><given-names>B.A.</given-names></name><name><surname>Dunlop</surname><given-names>M.</given-names></name><name><surname>Hodgson</surname><given-names>S.V.</given-names></name><name><surname>Iwama</surname><given-names>T.</given-names></name><name><surname>J&#x000e4;rvinen</surname><given-names>H.</given-names></name><name><surname>Kellokumpu</surname><given-names>I.</given-names></name><name><surname>Kim</surname><given-names>J.C.</given-names></name><name><surname>Leggett</surname><given-names>B.</given-names></name><name><surname>Markie</surname><given-names>D.</given-names></name><name><surname>Mecklin</surname><given-names>J.-P.</given-names></name><name><surname>Neale</surname><given-names>K.</given-names></name><name><surname>Phillips</surname><given-names>R.</given-names></name><name><surname>Piris</surname><given-names>J.</given-names></name><name><surname>Rozen</surname><given-names>P.</given-names></name><name><surname>Houlston</surname><given-names>R.S.</given-names></name><name><surname>Aaltonen</surname><given-names>L.A.</given-names></name><name><surname>Tomlinson</surname><given-names>I.P.M.</given-names></name><name><surname>Eng</surname><given-names>C.</given-names></name></person-group><article-title>Germline mutations in BMPR1A/ALK3 cause a subset of cases of juvenile polyposis syndrome and of Cowden and Bannayan-Riley-Ruvalcaba syndromes</article-title><source>Am. J. Hum. Genet.</source><volume>69</volume><issue>4</issue><year>2001</year><fpage>704</fpage><lpage>711</lpage><pub-id pub-id-type="pmid">11536076</pub-id></element-citation></ref><ref id="bb0050"><label>10</label><element-citation publication-type="journal" id="rf0050"><person-group person-group-type="author"><name><surname>Howe</surname><given-names>J.R.</given-names></name><name><surname>Bair</surname><given-names>J.L.</given-names></name><name><surname>Sayed</surname><given-names>M.G.</given-names></name><name><surname>Anderson</surname><given-names>M.E.</given-names></name><name><surname>Mitros</surname><given-names>F.A.</given-names></name><name><surname>Petersen</surname><given-names>G.M.</given-names></name><name><surname>Velculescu</surname><given-names>V.E.</given-names></name><name><surname>Traverso</surname><given-names>G.</given-names></name><name><surname>Vogelstein</surname><given-names>B.</given-names></name></person-group><article-title>Germline mutations of the gene encoding bone morphogenetic protein receptor 1A in juvenile polyposis</article-title><source>Nat. Genet.</source><volume>28</volume><issue>2</issue><year>2001</year><fpage>184</fpage><lpage>187</lpage><pub-id pub-id-type="pmid">11381269</pub-id></element-citation></ref><ref id="bb0055"><label>11</label><element-citation publication-type="journal" id="rf0055"><person-group person-group-type="author"><name><surname>Shore</surname><given-names>E.M.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Feldman</surname><given-names>G.J.</given-names></name><name><surname>Fenstermacher</surname><given-names>D.A.</given-names></name><name><surname>Cho</surname><given-names>T.J.</given-names></name><name><surname>Choi</surname><given-names>I.H.</given-names></name><name><surname>Connor</surname><given-names>J.M.</given-names></name><name><surname>Delai</surname><given-names>P.</given-names></name><name><surname>Glaser</surname><given-names>D.L.</given-names></name><name><surname>LeMerrer</surname><given-names>M.</given-names></name><name><surname>Morhart</surname><given-names>R.</given-names></name><name><surname>Rogers</surname><given-names>J.G.</given-names></name><name><surname>Smith</surname><given-names>R.</given-names></name><name><surname>Triffitt</surname><given-names>J.T.</given-names></name><name><surname>Urtizberea</surname><given-names>J.A.</given-names></name><name><surname>Zasloff</surname><given-names>M.</given-names></name><name><surname>Brown</surname><given-names>M.A.</given-names></name><name><surname>Kaplan</surname><given-names>F.S.</given-names></name></person-group><article-title>A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva</article-title><source>Nat. Genet.</source><volume>38</volume><issue>5</issue><year>2006</year><fpage>525</fpage><lpage>527</lpage><pub-id pub-id-type="pmid">16642017</pub-id></element-citation></ref><ref id="bb0060"><label>12</label><element-citation publication-type="journal" id="rf0060"><person-group person-group-type="author"><name><surname>Hatsell</surname><given-names>S.J.</given-names></name><name><surname>Idone</surname><given-names>V.</given-names></name><name><surname>Wolken</surname><given-names>D.M.A.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Kim</surname><given-names>H.J.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><name><surname>Wen</surname><given-names>X.</given-names></name><name><surname>Nannuru</surname><given-names>K.C.</given-names></name><name><surname>Jimenez</surname><given-names>J.</given-names></name><name><surname>Xie</surname><given-names>L.</given-names></name><name><surname>Das</surname><given-names>N.</given-names></name><name><surname>Makhoul</surname><given-names>G.</given-names></name><name><surname>Chernomorsky</surname><given-names>R.</given-names></name><name><surname>D'Ambrosio</surname><given-names>D.</given-names></name><name><surname>Corpina</surname><given-names>R.A.</given-names></name><name><surname>Schoenherr</surname><given-names>C.J.</given-names></name><name><surname>Feeley</surname><given-names>K.</given-names></name><name><surname>Yu</surname><given-names>P.B.</given-names></name><name><surname>Yancopoulos</surname><given-names>G.D.</given-names></name><name><surname>Murphy</surname><given-names>A.J.</given-names></name><name><surname>Economides</surname><given-names>A.N.</given-names></name></person-group><article-title>ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A</article-title><source>Sci. Transl. Med.</source><volume>7</volume><issue>303</issue><year>2015</year><fpage>303ra137</fpage></element-citation></ref><ref id="bb0065"><label>13</label><element-citation publication-type="journal" id="rf0065"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>K.R.</given-names></name><name><surname>Vinci</surname><given-names>M.</given-names></name><name><surname>Bullock</surname><given-names>A.N.</given-names></name><name><surname>Jones</surname><given-names>C.</given-names></name></person-group><article-title>ACVR1 mutations in DIPG: lessons learned from FOP</article-title><source>Cancer Res.</source><volume>74</volume><issue>17</issue><year>2014</year><fpage>4565</fpage><lpage>4570</lpage><pub-id pub-id-type="pmid">25136070</pub-id></element-citation></ref><ref id="bb0070"><label>14</label><element-citation publication-type="journal" id="rf0070"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>Y.J.</given-names></name><name><surname>Ingram</surname><given-names>P.N.</given-names></name><name><surname>Yang</surname><given-names>K.</given-names></name><name><surname>Coffman</surname><given-names>L.</given-names></name><name><surname>Iyengar</surname><given-names>M.</given-names></name><name><surname>Bai</surname><given-names>S.</given-names></name><name><surname>Thomas</surname><given-names>D.G.</given-names></name><name><surname>Yoon</surname><given-names>E.</given-names></name><name><surname>Buckanovich</surname><given-names>R.J.</given-names></name></person-group><article-title>Identifying an ovarian cancer cell hierarchy regulated by bone morphogenetic protein 2</article-title><source>Proc. Natl. Acad. Sci. U. S. A.</source><volume>112</volume><issue>50</issue><year>2015</year><fpage>E6882</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">26621735</pub-id></element-citation></ref><ref id="bb0075"><label>15</label><element-citation publication-type="journal" id="rf0075"><person-group person-group-type="author"><name><surname>Autzen</surname><given-names>P.</given-names></name><name><surname>Robson</surname><given-names>C.N.</given-names></name><name><surname>Bjartell</surname><given-names>A.</given-names></name><name><surname>Malcolm</surname><given-names>A.J.</given-names></name><name><surname>Johnson</surname><given-names>M.I.</given-names></name><name><surname>Neal</surname><given-names>D.E.</given-names></name><name><surname>Hamdy</surname><given-names>F.C.</given-names></name></person-group><article-title>Bone morphogenetic protein 6 in skeletal metastases from prostate cancer and other common human malignancies</article-title><source>Br. J. Cancer</source><volume>78</volume><issue>9</issue><year>1998</year><fpage>1219</fpage><lpage>1223</lpage><pub-id pub-id-type="pmid">9820184</pub-id></element-citation></ref><ref id="bb0080"><label>16</label><element-citation publication-type="journal" id="rf0080"><person-group person-group-type="author"><name><surname>Darby</surname><given-names>S.</given-names></name><name><surname>Cross</surname><given-names>S.S.</given-names></name><name><surname>Brown</surname><given-names>N.J.</given-names></name><name><surname>Hamdy</surname><given-names>F.C.</given-names></name><name><surname>Robson</surname><given-names>C.N.</given-names></name></person-group><article-title>BMP-6 over-expression in prostate cancer is associated with increased Id-1 protein and a more invasive phenotype</article-title><source>J. Pathol.</source><volume>214</volume><issue>3</issue><year>2008</year><fpage>394</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">18072288</pub-id></element-citation></ref><ref id="bb0085"><label>17</label><element-citation publication-type="journal" id="rf0085"><person-group person-group-type="author"><name><surname>Taylor</surname><given-names>K.R.</given-names></name><name><surname>Mackay</surname><given-names>A.</given-names></name><name><surname>Truffaux</surname><given-names>N.</given-names></name><name><surname>Butterfield</surname><given-names>Y.S.</given-names></name><name><surname>Morozova</surname><given-names>O.</given-names></name><name><surname>Philippe</surname><given-names>C.</given-names></name><name><surname>Castel</surname><given-names>D.</given-names></name><name><surname>Grasso</surname><given-names>C.S.</given-names></name><name><surname>Vinci</surname><given-names>M.</given-names></name><name><surname>Carvalho</surname><given-names>D.</given-names></name><name><surname>Carcaboso</surname><given-names>A.M.</given-names></name><name><surname>de Torres</surname><given-names>C.</given-names></name><name><surname>Cruz</surname><given-names>O.</given-names></name><name><surname>Mora</surname><given-names>J.</given-names></name><name><surname>Entz-Werle</surname><given-names>N.</given-names></name><name><surname>Ingram</surname><given-names>W.J.</given-names></name><name><surname>Monje</surname><given-names>M.</given-names></name><name><surname>Hargrave</surname><given-names>D.</given-names></name><name><surname>Bullock</surname><given-names>A.N.</given-names></name><name><surname>Puget</surname><given-names>S.</given-names></name><name><surname>Yip</surname><given-names>S.</given-names></name><name><surname>Jones</surname><given-names>C.</given-names></name><name><surname>Grill</surname><given-names>J.</given-names></name></person-group><article-title>Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma</article-title><source>Nat. Genet.</source><volume>46</volume><issue>5</issue><year>2014</year><fpage>457</fpage><lpage>461</lpage><pub-id pub-id-type="pmid">24705252</pub-id></element-citation></ref><ref id="bb0090"><label>18</label><element-citation publication-type="journal" id="rf0090"><person-group person-group-type="author"><name><surname>Hover</surname><given-names>L.D.</given-names></name><name><surname>Young</surname><given-names>C.D.</given-names></name><name><surname>Bhola</surname><given-names>N.E.</given-names></name><name><surname>Wilson</surname><given-names>A.J.</given-names></name><name><surname>Khabele</surname><given-names>D.</given-names></name><name><surname>Hong</surname><given-names>C.C.</given-names></name><name><surname>Moses</surname><given-names>H.L.</given-names></name><name><surname>Owens</surname><given-names>P.</given-names></name></person-group><article-title>Small molecule inhibitor of the bone morphogenetic protein pathway DMH1 reduces ovarian cancer cell growth</article-title><source>Cancer Lett.</source><volume>368</volume><issue>1</issue><year>2015</year><fpage>79</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">26235139</pub-id></element-citation></ref><ref id="bb0095"><label>19</label><element-citation publication-type="journal" id="rf0095"><person-group person-group-type="author"><name><surname>Fotinos</surname><given-names>A.</given-names></name><name><surname>Nagarajan</surname><given-names>N.</given-names></name><name><surname>Martins</surname><given-names>A.S.</given-names></name><name><surname>Fritz</surname><given-names>D.T.</given-names></name><name><surname>Garsetti</surname><given-names>D.</given-names></name><name><surname>Lee</surname><given-names>A.T.</given-names></name><name><surname>Hong</surname><given-names>C.C.</given-names></name><name><surname>Rogers</surname><given-names>M.B.</given-names></name></person-group><article-title>Bone morphogenetic protein-focused strategies to induce cytotoxicity in lung cancer cells</article-title><source>Anticancer Res.</source><volume>34</volume><issue>5</issue><year>2014</year><fpage>2095</fpage><lpage>2104</lpage><pub-id pub-id-type="pmid">24778011</pub-id></element-citation></ref><ref id="bb0100"><label>20</label><element-citation publication-type="journal" id="rf0100"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>P.</given-names></name><name><surname>Polikowsky</surname><given-names>H.</given-names></name><name><surname>Pickup</surname><given-names>M.W.</given-names></name><name><surname>Gorska</surname><given-names>A.E.</given-names></name><name><surname>Jovanovic</surname><given-names>B.</given-names></name><name><surname>Shaw</surname><given-names>A.K.</given-names></name><name><surname>Novitskiy</surname><given-names>S.V.</given-names></name><name><surname>Hong</surname><given-names>C.C.</given-names></name><name><surname>Moses</surname><given-names>H.L.</given-names></name></person-group><article-title>Bone morphogenetic proteins stimulate mammary fibroblasts to promote mammary carcinoma cell invasion</article-title><source>PLoS One</source><volume>8</volume><issue>6</issue><year>2013</year><object-id pub-id-type="publisher-id">e67533</object-id></element-citation></ref><ref id="bb0105"><label>21</label><element-citation publication-type="journal" id="rf0105"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>P.</given-names></name><name><surname>Pickup</surname><given-names>M.W.</given-names></name><name><surname>Novitskiy</surname><given-names>S.V.</given-names></name><name><surname>Giltnane</surname><given-names>J.M.</given-names></name><name><surname>Gorska</surname><given-names>A.E.</given-names></name><name><surname>Hopkins</surname><given-names>C.R.</given-names></name><name><surname>Hong</surname><given-names>C.C.</given-names></name><name><surname>Moses</surname><given-names>H.L.</given-names></name></person-group><article-title>Inhibition of BMP signaling suppresses metastasis in mammary cancer</article-title><source>Oncogene</source><volume>34</volume><issue>19</issue><year>2015</year><fpage>2437</fpage><lpage>2449</lpage><pub-id pub-id-type="pmid">24998846</pub-id></element-citation></ref><ref id="bb0110"><label>22</label><element-citation publication-type="journal" id="rf0110"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>Y.-C.</given-names></name><name><surname>Cheng</surname><given-names>C.-J.</given-names></name><name><surname>Bilen</surname><given-names>M.A.</given-names></name><name><surname>Lu</surname><given-names>J.-F.</given-names></name><name><surname>Satcher</surname><given-names>R.L.</given-names></name><name><surname>Yu-Lee</surname><given-names>L.-Y.</given-names></name><name><surname>Gallick</surname><given-names>G.E.</given-names></name><name><surname>Maity</surname><given-names>S.N.</given-names></name><name><surname>Lin</surname><given-names>S.-H.</given-names></name></person-group><article-title>BMP4 promotes prostate tumor growth in bone through osteogenesis</article-title><source>Cancer Res.</source><volume>71</volume><issue>15</issue><year>2011</year><fpage>5194</fpage><lpage>5203</lpage><pub-id pub-id-type="pmid">21670081</pub-id></element-citation></ref><ref id="bb0115"><label>23</label><element-citation publication-type="journal" id="rf0115"><person-group person-group-type="author"><name><surname>Ali</surname><given-names>J.L.</given-names></name><name><surname>Lagasse</surname><given-names>B.J.</given-names></name><name><surname>Minuk</surname><given-names>A.J.</given-names></name><name><surname>Love</surname><given-names>A.J.</given-names></name><name><surname>Moraya</surname><given-names>A.I.</given-names></name><name><surname>Lam</surname><given-names>L.</given-names></name><name><surname>Arthur</surname><given-names>G.</given-names></name><name><surname>Gibson</surname><given-names>S.B.</given-names></name><name><surname>Morrison</surname><given-names>L.C.</given-names></name><name><surname>Werbowetski-Ogilvie</surname><given-names>T.E.</given-names></name><name><surname>Fu</surname><given-names>Y.</given-names></name><name><surname>Nachtigal</surname><given-names>M.W.</given-names></name></person-group><article-title>Differential cellular responses induced by dorsomorphin and LDN-193189 in chemotherapy-sensitive and chemotherapy-resistant human epithelial ovarian cancer cells</article-title><source>Int. J. Cancer</source><volume>136</volume><issue>5</issue><year>2015</year><fpage>E455</fpage><lpage>E469</lpage><pub-id pub-id-type="pmid">25227893</pub-id></element-citation></ref><ref id="bb0120"><label>24</label><element-citation publication-type="journal" id="rf0120"><person-group person-group-type="author"><name><surname>Shen</surname><given-names>Z.</given-names></name><name><surname>Sepp&#x000e4;nen</surname><given-names>H.</given-names></name><name><surname>Kauttu</surname><given-names>T.</given-names></name><name><surname>Vainionp&#x000e4;&#x000e4;</surname><given-names>S.</given-names></name><name><surname>Ye</surname><given-names>Y.</given-names></name><name><surname>Wang</surname><given-names>S.</given-names></name><name><surname>Mustonen</surname><given-names>H.</given-names></name><name><surname>Puolakkainen</surname><given-names>P.</given-names></name></person-group><article-title>Vasohibin-1 expression is regulated by transforming growth factor-&#x003b2;/bone morphogenic protein signaling pathway between tumor-associated macrophages and pancreatic cancer cells</article-title><source>J. Interf. Cytokine Res.</source><volume>33</volume><issue>8</issue><year>2013</year><fpage>428</fpage><lpage>433</lpage></element-citation></ref><ref id="bb0125"><label>25</label><element-citation publication-type="journal" id="rf0125"><person-group person-group-type="author"><name><surname>Raymond</surname><given-names>A.</given-names></name><name><surname>Liu</surname><given-names>B.</given-names></name><name><surname>Liang</surname><given-names>H.</given-names></name><name><surname>Wei</surname><given-names>C.</given-names></name><name><surname>Guindani</surname><given-names>M.</given-names></name><name><surname>Lu</surname><given-names>Y.</given-names></name><name><surname>Liang</surname><given-names>S.</given-names></name><name><surname>John</surname><given-names>L.S.St.</given-names></name><name><surname>Molldrem</surname><given-names>J.</given-names></name><name><surname>Nagarajan</surname><given-names>L.</given-names></name></person-group><article-title>A role for BMP-induced homeobox gene MIXL1 in acute myelogenous leukemia and identification of type I BMP receptor as a potential target for therapy</article-title><source>Oncotarget</source><volume>5</volume><issue>24</issue><year>2014</year><fpage>12675</fpage><lpage>12693</lpage><pub-id pub-id-type="pmid">25544748</pub-id></element-citation></ref><ref id="bb0130"><label>26</label><element-citation publication-type="journal" id="rf0130"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>P.B.</given-names></name><name><surname>Hong</surname><given-names>C.C.</given-names></name><name><surname>Sachidanandan</surname><given-names>C.</given-names></name><name><surname>Babitt</surname><given-names>J.L.</given-names></name><name><surname>Deng</surname><given-names>D.Y.</given-names></name><name><surname>Hoyng</surname><given-names>S.A.</given-names></name><name><surname>Lin</surname><given-names>H.Y.</given-names></name><name><surname>Bloch</surname><given-names>K.D.</given-names></name><name><surname>Peterson</surname><given-names>R.T.</given-names></name></person-group><article-title>Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism</article-title><source>Nat. Chem. Biol.</source><volume>4</volume><issue>1</issue><year>2008</year><fpage>33</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">18026094</pub-id></element-citation></ref><ref id="bb0135"><label>27</label><element-citation publication-type="journal" id="rf0135"><person-group person-group-type="author"><name><surname>Steinbicker</surname><given-names>A.U.</given-names></name><name><surname>Sachidanandan</surname><given-names>C.</given-names></name><name><surname>Vonner</surname><given-names>A.J.</given-names></name><name><surname>Yusuf</surname><given-names>R.Z.</given-names></name><name><surname>Deng</surname><given-names>D.Y.</given-names></name><name><surname>Lai</surname><given-names>C.S.</given-names></name><name><surname>Rauwerdink</surname><given-names>K.M.</given-names></name><name><surname>Winn</surname><given-names>J.C.</given-names></name><name><surname>Saez</surname><given-names>B.</given-names></name><name><surname>Cook</surname><given-names>C.M.</given-names></name><name><surname>Szekely</surname><given-names>B.A.</given-names></name><name><surname>Roy</surname><given-names>C.N.</given-names></name><name><surname>Seehra</surname><given-names>J.S.</given-names></name><name><surname>Cuny</surname><given-names>G.D.</given-names></name><name><surname>Scadden</surname><given-names>D.T.</given-names></name><name><surname>Peterson</surname><given-names>R.T.</given-names></name><name><surname>Bloch</surname><given-names>K.D.</given-names></name><name><surname>Yu</surname><given-names>P.B.</given-names></name></person-group><article-title>Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation</article-title><source>Blood</source><volume>117</volume><issue>18</issue><year>2011</year><fpage>4915</fpage><lpage>4923</lpage><pub-id pub-id-type="pmid">21393479</pub-id></element-citation></ref><ref id="bb0140"><label>28</label><element-citation publication-type="journal" id="rf0140"><person-group person-group-type="author"><name><surname>Lowery</surname><given-names>J.W.</given-names></name><name><surname>Brookshire</surname><given-names>B.</given-names></name><name><surname>Rosen</surname><given-names>V.</given-names></name></person-group><article-title>A survey of strategies to modulate the bone morphogenetic protein signaling pathway: current and future perspectives</article-title><source>Stem Cells Int.</source><volume>2016</volume><year>2016</year><fpage>7290686</fpage><pub-id pub-id-type="pmid">27433166</pub-id></element-citation></ref><ref id="bb0145"><label>29</label><element-citation publication-type="journal" id="rf0145"><person-group person-group-type="author"><name><surname>Chaikuad</surname><given-names>A.</given-names></name><name><surname>Alfano</surname><given-names>I.</given-names></name><name><surname>Kerr</surname><given-names>G.</given-names></name><name><surname>Sanvitale</surname><given-names>C.E.</given-names></name><name><surname>Boergermann</surname><given-names>J.H.</given-names></name><name><surname>Triffitt</surname><given-names>J.T.</given-names></name><name><surname>von Delft</surname><given-names>F.</given-names></name><name><surname>Knapp</surname><given-names>S.</given-names></name><name><surname>Knaus</surname><given-names>P.</given-names></name><name><surname>Bullock</surname><given-names>A.N.</given-names></name></person-group><article-title>Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva</article-title><source>J. Biol. Chem.</source><volume>287</volume><issue>44</issue><year>2012</year><fpage>36990</fpage><lpage>36998</lpage><pub-id pub-id-type="pmid">22977237</pub-id></element-citation></ref><ref id="bb0150"><label>30</label><element-citation publication-type="journal" id="rf0150"><person-group person-group-type="author"><name><surname>Cuny</surname><given-names>G.D.</given-names></name><name><surname>Yu</surname><given-names>P.B.</given-names></name><name><surname>Laha</surname><given-names>J.K.</given-names></name><name><surname>Xing</surname><given-names>X.</given-names></name><name><surname>Liu</surname><given-names>J.-F.</given-names></name><name><surname>Lai</surname><given-names>C.S.</given-names></name><name><surname>Deng</surname><given-names>D.Y.</given-names></name><name><surname>Sachidanandan</surname><given-names>C.</given-names></name><name><surname>Bloch</surname><given-names>K.D.</given-names></name><name><surname>Peterson</surname><given-names>R.T.</given-names></name></person-group><article-title>Structure-activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors</article-title><source>Bioorg. Med. Chem. Lett.</source><volume>18</volume><issue>15</issue><year>2008</year><fpage>4388</fpage><lpage>4392</lpage><pub-id pub-id-type="pmid">18621530</pub-id></element-citation></ref><ref id="bb0155"><label>31</label><element-citation publication-type="journal" id="rf0155"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>J.</given-names></name><name><surname>Ho</surname><given-names>J.N.</given-names></name><name><surname>Lewis</surname><given-names>J.A.</given-names></name><name><surname>Karim</surname><given-names>K.A.</given-names></name><name><surname>Daniels</surname><given-names>R.N.</given-names></name><name><surname>Gentry</surname><given-names>P.R.</given-names></name><name><surname>Hopkins</surname><given-names>C.R.</given-names></name><name><surname>Lindsley</surname><given-names>C.W.</given-names></name><name><surname>Hong</surname><given-names>C.C.</given-names></name></person-group><article-title>In vivo structure activity relationship study of dorsomorphin analogs identifies selective VEGF and BMP inhibitors</article-title><source>ACS Chem. Biol.</source><volume>5</volume><issue>2</issue><year>2010</year><fpage>245</fpage><lpage>253</lpage><pub-id pub-id-type="pmid">20020776</pub-id></element-citation></ref><ref id="bb0160"><label>32</label><element-citation publication-type="journal" id="rf0160"><person-group person-group-type="author"><name><surname>Tsugawa</surname><given-names>D.</given-names></name><name><surname>Oya</surname><given-names>Y.</given-names></name><name><surname>Masuzaki</surname><given-names>R.</given-names></name><name><surname>Ray</surname><given-names>K.</given-names></name><name><surname>Engers</surname><given-names>D.W.</given-names></name><name><surname>Dib</surname><given-names>M.</given-names></name><name><surname>Do</surname><given-names>N.</given-names></name><name><surname>Kuramitsu</surname><given-names>K.</given-names></name><name><surname>Ho</surname><given-names>K.</given-names></name><name><surname>Frist</surname><given-names>A.</given-names></name><name><surname>Yu</surname><given-names>P.B.</given-names></name><name><surname>Bloch</surname><given-names>K.D.</given-names></name><name><surname>Lindsley</surname><given-names>C.W.</given-names></name><name><surname>Hopkins</surname><given-names>C.R.</given-names></name><name><surname>Hong</surname><given-names>C.C.</given-names></name><name><surname>Karp</surname><given-names>S.J.</given-names></name></person-group><article-title>Specific activin receptor&#x02013;like kinase 3 inhibitors enhance liver regeneration</article-title><source>J. Pharmacol. Exp. Ther.</source><volume>351</volume><issue>3</issue><year>2014</year><fpage>549</fpage><lpage>558</lpage><pub-id pub-id-type="pmid">25271257</pub-id></element-citation></ref><ref id="bb0165"><label>33</label><element-citation publication-type="journal" id="rf0165"><person-group person-group-type="author"><name><surname>Mohedas</surname><given-names>A.H.</given-names></name><name><surname>Xing</surname><given-names>X.</given-names></name><name><surname>Armstrong</surname><given-names>K.A.</given-names></name><name><surname>Bullock</surname><given-names>A.N.</given-names></name><name><surname>Cuny</surname><given-names>G.D.</given-names></name><name><surname>Yu</surname><given-names>P.B.</given-names></name></person-group><article-title>Development of an ALK2-biased BMP type I receptor kinase inhibitor</article-title><source>ACS Chem. Biol.</source><volume>8</volume><issue>6</issue><year>2013</year><fpage>1291</fpage><lpage>1302</lpage><pub-id pub-id-type="pmid">23547776</pub-id></element-citation></ref><ref id="bb0170"><label>34</label><element-citation publication-type="journal" id="rf0170"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>P.B.</given-names></name><name><surname>Deng</surname><given-names>D.Y.</given-names></name><name><surname>Lai</surname><given-names>C.S.</given-names></name><name><surname>Hong</surname><given-names>C.C.</given-names></name><name><surname>Cuny</surname><given-names>G.D.</given-names></name><name><surname>Bouxsein</surname><given-names>M.L.</given-names></name><name><surname>Hong</surname><given-names>D.W.</given-names></name><name><surname>McManus</surname><given-names>P.M.</given-names></name><name><surname>Katagiri</surname><given-names>T.</given-names></name><name><surname>Sachidanandan</surname><given-names>C.</given-names></name><name><surname>Kamiya</surname><given-names>N.</given-names></name><name><surname>Fukuda</surname><given-names>T.</given-names></name><name><surname>Mishina</surname><given-names>Y.</given-names></name><name><surname>Peterson</surname><given-names>R.T.</given-names></name><name><surname>Bloch</surname><given-names>K.D.</given-names></name></person-group><article-title>BMP type I receptor inhibition reduces heterotopic ossification</article-title><source>Nat. Med.</source><volume>14</volume><issue>12</issue><year>2008</year><fpage>1363</fpage><lpage>1369</lpage><pub-id pub-id-type="pmid">19029982</pub-id></element-citation></ref><ref id="bb0175"><label>35</label><element-citation publication-type="journal" id="rf0175"><person-group person-group-type="author"><name><surname>Derwall</surname><given-names>M.</given-names></name><name><surname>Malhotra</surname><given-names>R.</given-names></name><name><surname>Lai</surname><given-names>C.S.</given-names></name><name><surname>Beppu</surname><given-names>Y.</given-names></name><name><surname>Aikawa</surname><given-names>E.</given-names></name><name><surname>Seehra</surname><given-names>J.S.</given-names></name><name><surname>Zapol</surname><given-names>W.M.</given-names></name><name><surname>Bloch</surname><given-names>K.D.</given-names></name><name><surname>Yu</surname><given-names>P.B.</given-names></name></person-group><article-title>Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis</article-title><source>Arterioscler. Thromb. Vasc. Biol.</source><volume>32</volume><issue>3</issue><year>2012</year><comment>(613-U168)</comment></element-citation></ref><ref id="bb0180"><label>36</label><element-citation publication-type="journal" id="rf0180"><person-group person-group-type="author"><name><surname>Sanvitale</surname><given-names>C.E.</given-names></name><name><surname>Kerr</surname><given-names>G.</given-names></name><name><surname>Chaikuad</surname><given-names>A.</given-names></name><name><surname>Ramel</surname><given-names>M.-C.</given-names></name><name><surname>Mohedas</surname><given-names>A.H.</given-names></name><name><surname>Reichert</surname><given-names>S.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Triffitt</surname><given-names>J.T.</given-names></name><name><surname>Cuny</surname><given-names>G.D.</given-names></name><name><surname>Yu</surname><given-names>P.B.</given-names></name><name><surname>Hill</surname><given-names>C.S.</given-names></name><name><surname>Bullock</surname><given-names>A.N.</given-names></name></person-group><article-title>A new class of small molecule inhibitor of BMP signaling</article-title><source>PLoS One</source><volume>8</volume><issue>4</issue><year>2013</year></element-citation></ref><ref id="bb0185"><label>37</label><element-citation publication-type="journal" id="rf0185"><person-group person-group-type="author"><name><surname>Mohedas</surname><given-names>A.H.</given-names></name><name><surname>Wang</surname><given-names>Y.</given-names></name><name><surname>Sanvitale</surname><given-names>C.E.</given-names></name><name><surname>Canning</surname><given-names>P.</given-names></name><name><surname>Choi</surname><given-names>S.</given-names></name><name><surname>Xing</surname><given-names>X.</given-names></name><name><surname>Bullock</surname><given-names>A.N.</given-names></name><name><surname>Cuny</surname><given-names>G.D.</given-names></name><name><surname>Yu</surname><given-names>P.B.</given-names></name></person-group><article-title>Structure&#x02013;activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants</article-title><source>J. Med. Chem.</source><volume>57</volume><issue>19</issue><year>2014</year><fpage>7900</fpage><lpage>7915</lpage><pub-id pub-id-type="pmid">25101911</pub-id></element-citation></ref><ref id="bb0190"><label>38</label><element-citation publication-type="journal" id="rf0190"><person-group person-group-type="author"><name><surname>Hopkins</surname><given-names>C.R.</given-names></name></person-group><article-title>Inhibitors of the bone morphogenetic protein (BMP) signaling pathway: a patent review (2008&#x02013;2015)</article-title><source>Expert Opin. Ther. Pat.</source><volume>26</volume><issue>10</issue><year>2016</year><fpage>1115</fpage><lpage>1128</lpage></element-citation></ref><ref id="bb0195"><label>39</label><element-citation publication-type="journal" id="rf0195"><person-group person-group-type="author"><name><surname>Dey</surname><given-names>D.</given-names></name><name><surname>Bagarova</surname><given-names>J.</given-names></name><name><surname>Hatsell</surname><given-names>S.J.</given-names></name><name><surname>Armstrong</surname><given-names>K.A.</given-names></name><name><surname>Huang</surname><given-names>L.</given-names></name><name><surname>Ermann</surname><given-names>J.</given-names></name><name><surname>Vonner</surname><given-names>A.J.</given-names></name><name><surname>Shen</surname><given-names>Y.</given-names></name><name><surname>Mohedas</surname><given-names>A.H.</given-names></name><name><surname>Lee</surname><given-names>A.</given-names></name><name><surname>Eekhoff</surname><given-names>E.M.</given-names></name><name><surname>van Schie</surname><given-names>A.</given-names></name><name><surname>Demay</surname><given-names>M.B.</given-names></name><name><surname>Keller</surname><given-names>C.</given-names></name><name><surname>Wagers</surname><given-names>A.J.</given-names></name><name><surname>Economides</surname><given-names>A.N.</given-names></name><name><surname>Yu</surname><given-names>P.B.</given-names></name></person-group><article-title>Two tissue-resident progenitor lineages drive distinct phenotypes of heterotopic ossification</article-title><source>Sci. Transl. Med.</source><volume>8</volume><issue>366</issue><year>2016</year><object-id pub-id-type="publisher-id">366ra163</object-id></element-citation></ref><ref id="bb0200"><label>40</label><element-citation publication-type="journal" id="rf0200"><person-group person-group-type="author"><name><surname>Leslie</surname><given-names>A.G.</given-names></name></person-group><article-title>The integration of macromolecular diffraction data</article-title><source>Acta Crystallogr. D Biol. Crystallogr.</source><volume>62</volume><issue>Pt 1</issue><year>2006</year><fpage>48</fpage><lpage>57</lpage><pub-id pub-id-type="pmid">16369093</pub-id></element-citation></ref><ref id="bb0205"><label>41</label><element-citation publication-type="journal" id="rf0205"><person-group person-group-type="author"><name><surname>Winn</surname><given-names>M.D.</given-names></name><name><surname>Ballard</surname><given-names>C.C.</given-names></name><name><surname>Cowtan</surname><given-names>K.D.</given-names></name><name><surname>Dodson</surname><given-names>E.J.</given-names></name><name><surname>Emsley</surname><given-names>P.</given-names></name><name><surname>Evans</surname><given-names>P.R.</given-names></name><name><surname>Keegan</surname><given-names>R.M.</given-names></name><name><surname>Krissinel</surname><given-names>E.B.</given-names></name><name><surname>Leslie</surname><given-names>A.G.W.</given-names></name><name><surname>McCoy</surname><given-names>A.</given-names></name><name><surname>McNicholas</surname><given-names>S.J.</given-names></name><name><surname>Murshudov</surname><given-names>G.N.</given-names></name><name><surname>Pannu</surname><given-names>N.S.</given-names></name><name><surname>Potterton</surname><given-names>E.A.</given-names></name><name><surname>Powell</surname><given-names>H.R.</given-names></name><name><surname>Read</surname><given-names>R.J.</given-names></name><name><surname>Vagin</surname><given-names>A.</given-names></name><name><surname>Wilson</surname><given-names>K.S.</given-names></name></person-group><article-title>Overview of the CCP4 suite and current developments</article-title><source>Acta Crystallogr. D Biol. Crystallogr.</source><volume>67</volume><year>2011</year><fpage>235</fpage><lpage>242</lpage><pub-id pub-id-type="pmid">21460441</pub-id></element-citation></ref><ref id="bb0210"><label>42</label><element-citation publication-type="journal" id="rf0210"><person-group person-group-type="author"><name><surname>McCoy</surname><given-names>A.J.</given-names></name><name><surname>Grosse-Kunstleve</surname><given-names>R.W.</given-names></name><name><surname>Adams</surname><given-names>P.D.</given-names></name><name><surname>Winn</surname><given-names>M.D.</given-names></name><name><surname>Storoni</surname><given-names>L.C.</given-names></name><name><surname>Read</surname><given-names>R.J.</given-names></name></person-group><article-title>Phaser crystallographic software</article-title><source>J. Appl. Crystallogr.</source><volume>40</volume><issue>Pt 4</issue><year>2007</year><fpage>658</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">19461840</pub-id></element-citation></ref><ref id="bb0215"><label>43</label><element-citation publication-type="journal" id="rf0215"><person-group person-group-type="author"><name><surname>Murshudov</surname><given-names>G.N.</given-names></name><name><surname>Vagin</surname><given-names>A.A.</given-names></name><name><surname>Dodson</surname><given-names>E.J.</given-names></name></person-group><article-title>Refinement of macromolecular structures by the maximum-likelihood method</article-title><source>Acta Crystallogr. D Biol. Crystallogr.</source><volume>53</volume><issue>Pt 3</issue><year>1997</year><fpage>240</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">15299926</pub-id></element-citation></ref><ref id="bb0220"><label>44</label><element-citation publication-type="journal" id="rf0220"><person-group person-group-type="author"><name><surname>Emsley</surname><given-names>P.</given-names></name><name><surname>Cowtan</surname><given-names>K.</given-names></name></person-group><article-title>Coot: model-building tools for molecular graphics</article-title><source>Acta Crystallogr. D Biol. Crystallogr.</source><volume>60</volume><year>2004</year><fpage>2126</fpage><lpage>2132</lpage><pub-id pub-id-type="pmid">15572765</pub-id></element-citation></ref><ref id="bb0225"><label>45</label><element-citation publication-type="journal" id="rf0225"><person-group person-group-type="author"><name><surname>Painter</surname><given-names>J.</given-names></name><name><surname>Merritt</surname><given-names>E.A.</given-names></name></person-group><article-title>Optimal description of a protein structure in terms of multiple groups undergoing TLS motion</article-title><source>Acta Crystallogr. D Biol. Crystallogr.</source><volume>62</volume><year>2006</year><fpage>439</fpage><lpage>450</lpage><pub-id pub-id-type="pmid">16552146</pub-id></element-citation></ref><ref id="bb0230"><label>46</label><element-citation publication-type="journal" id="rf0230"><person-group person-group-type="author"><name><surname>Davis</surname><given-names>I.W.</given-names></name><name><surname>Leaver-Fay</surname><given-names>A.</given-names></name><name><surname>Chen</surname><given-names>V.B.</given-names></name><name><surname>Block</surname><given-names>J.N.</given-names></name><name><surname>Kapral</surname><given-names>G.J.</given-names></name><name><surname>Wang</surname><given-names>X.</given-names></name><name><surname>Murray</surname><given-names>L.W.</given-names></name><name><surname>Arendall</surname><given-names>W.B.</given-names><suffix>3rd</suffix></name><name><surname>Snoeyink</surname><given-names>J.</given-names></name><name><surname>Richardson</surname><given-names>J.S.</given-names></name><name><surname>Richardson</surname><given-names>D.C.</given-names></name></person-group><article-title>MolProbity: all-atom contacts and structure validation for proteins and nucleic acids</article-title><source>Nucleic Acids Res.</source><volume>35</volume><year>2007</year><fpage>W375</fpage><lpage>83</lpage><comment>(Web Server issue)</comment><pub-id pub-id-type="pmid">17452350</pub-id></element-citation></ref><ref id="bb0235"><label>47</label><element-citation publication-type="journal" id="rf0235"><person-group person-group-type="author"><name><surname>Horbelt</surname><given-names>D.</given-names></name><name><surname>Boergermann</surname><given-names>J.H.</given-names></name><name><surname>Chaikuad</surname><given-names>A.</given-names></name><name><surname>Alfano</surname><given-names>I.</given-names></name><name><surname>Williams</surname><given-names>E.</given-names></name><name><surname>Lukonin</surname><given-names>I.</given-names></name><name><surname>Timmel</surname><given-names>T.</given-names></name><name><surname>Bullock</surname><given-names>A.N.</given-names></name><name><surname>Knaus</surname><given-names>P.</given-names></name></person-group><article-title>Small molecules dorsomorphin and LDN-193189 inhibit myostatin/GDF8 signaling and promote functional myoblast differentiation</article-title><source>J. Biol. Chem.</source><volume>290</volume><issue>6</issue><year>2015</year><fpage>3390</fpage><lpage>3404</lpage><pub-id pub-id-type="pmid">25368322</pub-id></element-citation></ref><ref id="bb0240"><label>48</label><element-citation publication-type="journal" id="rf0240"><person-group person-group-type="author"><name><surname>Handa</surname><given-names>N.</given-names></name><name><surname>Takagi</surname><given-names>T.</given-names></name><name><surname>Saijo</surname><given-names>S.</given-names></name><name><surname>Kishishita</surname><given-names>S.</given-names></name><name><surname>Takaya</surname><given-names>D.</given-names></name><name><surname>Toyama</surname><given-names>M.</given-names></name><name><surname>Terada</surname><given-names>T.</given-names></name><name><surname>Shirouzu</surname><given-names>M.</given-names></name><name><surname>Suzuki</surname><given-names>A.</given-names></name><name><surname>Lee</surname><given-names>S.</given-names></name><name><surname>Yamauchi</surname><given-names>T.</given-names></name><name><surname>Okada-Iwabu</surname><given-names>M.</given-names></name><name><surname>Iwabu</surname><given-names>M.</given-names></name><name><surname>Kadowaki</surname><given-names>T.</given-names></name><name><surname>Minokoshi</surname><given-names>Y.</given-names></name><name><surname>Yokoyama</surname><given-names>S.</given-names></name></person-group><article-title>Structural basis for compound C inhibition of the human AMP-activated protein kinase [alpha]2 subunit kinase domain</article-title><source>Acta Crystallogr. D Biol. Crystallogr.</source><volume>67</volume><issue>5</issue><year>2011</year><fpage>480</fpage><lpage>487</lpage><pub-id pub-id-type="pmid">21543851</pub-id></element-citation></ref><ref id="bb0245"><label>49</label><element-citation publication-type="journal" id="rf0245"><person-group person-group-type="author"><name><surname>Kerr</surname><given-names>G.</given-names></name><name><surname>Sheldon</surname><given-names>H.</given-names></name><name><surname>Chaikuad</surname><given-names>A.</given-names></name><name><surname>Alfano</surname><given-names>I.</given-names></name><name><surname>Delft</surname><given-names>F.</given-names></name><name><surname>Bullock</surname><given-names>A.N.</given-names></name><name><surname>Harris</surname><given-names>A.L.</given-names></name></person-group><article-title>A small molecule targeting ALK1 prevents Notch cooperativity and inhibits functional angiogenesis</article-title><source>Angiogenesis</source><volume>18</volume><issue>2</issue><year>2015</year><fpage>209</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">25557927</pub-id></element-citation></ref><ref id="bb0250"><label>50</label><element-citation publication-type="journal" id="rf0250"><person-group person-group-type="author"><name><surname>Tebben</surname><given-names>A.J.</given-names></name><name><surname>Ruzanov</surname><given-names>M.</given-names></name><name><surname>Gao</surname><given-names>M.</given-names></name><name><surname>Xie</surname><given-names>D.</given-names></name><name><surname>Kiefer</surname><given-names>S.E.</given-names></name><name><surname>Yan</surname><given-names>C.</given-names></name><name><surname>Newitt</surname><given-names>J.A.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Kim</surname><given-names>K.</given-names></name><name><surname>Lu</surname><given-names>H.</given-names></name><name><surname>Kopcho</surname><given-names>L.M.</given-names></name><name><surname>Sheriff</surname><given-names>S.</given-names></name></person-group><article-title>Crystal structures of apo and inhibitor-bound TGFbetaR2 kinase domain: insights into TGFbetaR isoform selectivity</article-title><source>Acta Crystallogr. D Struct. Biol.</source><volume>72</volume><issue>Pt 5</issue><year>2016</year><fpage>658</fpage><lpage>674</lpage><pub-id pub-id-type="pmid">27139629</pub-id></element-citation></ref><ref id="bb0255"><label>51</label><element-citation publication-type="journal" id="rf0255"><person-group person-group-type="author"><name><surname>Sabat</surname><given-names>M.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Scorah</surname><given-names>N.</given-names></name><name><surname>Lawson</surname><given-names>J.D.</given-names></name><name><surname>Atienza</surname><given-names>J.</given-names></name><name><surname>Kamran</surname><given-names>R.</given-names></name><name><surname>Hixon</surname><given-names>M.S.</given-names></name><name><surname>Dougan</surname><given-names>D.R.</given-names></name></person-group><article-title>Design, synthesis and optimization of 7-substituted-pyrazolo[4,3-b]pyridine ALK5 (activin receptor-like kinase 5) inhibitors</article-title><source>Bioorg. Med. Chem. Lett.</source><volume>27</volume><issue>9</issue><year>2017</year><fpage>1955</fpage><lpage>1961</lpage><pub-id pub-id-type="pmid">28359790</pub-id></element-citation></ref><ref id="bb0260"><label>52</label><element-citation publication-type="journal" id="rf0260"><person-group person-group-type="author"><name><surname>Kovacs</surname><given-names>R.J.</given-names></name><name><surname>Maldonado</surname><given-names>G.</given-names></name><name><surname>Azaro</surname><given-names>A.</given-names></name><name><surname>Fernandez</surname><given-names>M.S.</given-names></name><name><surname>Romero</surname><given-names>F.L.</given-names></name><name><surname>Sepulveda-Sanchez</surname><given-names>J.M.</given-names></name><name><surname>Corretti</surname><given-names>M.</given-names></name><name><surname>Carducci</surname><given-names>M.</given-names></name><name><surname>Dolan</surname><given-names>M.</given-names></name><name><surname>Gueorguieva</surname><given-names>I.</given-names></name><name><surname>Cleverly</surname><given-names>A.L.</given-names></name><name><surname>Pillay</surname><given-names>N.S.</given-names></name><name><surname>Baselga</surname><given-names>J.</given-names></name><name><surname>Lahn</surname><given-names>M.M.</given-names></name></person-group><article-title>Cardiac safety of TGF-beta receptor I kinase inhibitor LY2157299 monohydrate in cancer patients in a first-in-human dose study</article-title><source>Cardiovasc. Toxicol.</source><volume>15</volume><issue>4</issue><year>2015</year><fpage>309</fpage><lpage>323</lpage><pub-id pub-id-type="pmid">25488804</pub-id></element-citation></ref><ref id="bb0265"><label>53</label><element-citation publication-type="journal" id="rf0265"><person-group person-group-type="author"><name><surname>Fairclough</surname><given-names>R.J.</given-names></name><name><surname>Wood</surname><given-names>M.J.</given-names></name><name><surname>Davies</surname><given-names>K.E.</given-names></name></person-group><article-title>Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches</article-title><source>Nat. Rev. Genet.</source><volume>14</volume><issue>6</issue><year>2013</year><fpage>373</fpage><lpage>378</lpage><pub-id pub-id-type="pmid">23609411</pub-id></element-citation></ref></ref-list><ack id="ac0005"><sec id="s0075"><title>Acknowledgements</title><p id="p0125">The authors would like to thank Diamond Light Source for beamtime (proposal mx8421), as well as the staff of beamline I03 for assistance with data collection. We thank Drs Greg Cuny and Paul Yu (Harvard University) for supplying the LDN-212854 inhibitor.</p></sec><sec id="s0080"><title>Funding</title><p id="p0130">The SGC is a registered charity (number 1097737) that receives funds from AbbVie, Bayer Pharma AG, Boehringer Ingelheim, Canada Foundation for Innovation, Eshelman Institute for Innovation, Genome Canada, Innovative Medicines Initiative (EU/EFPIA) [ULTRA-DD grant no. 115766], Janssen, Merck &#x00026; Co., Novartis Pharma AG, Ontario Ministry of Economic Development and Innovation, Pfizer, S&#x000e3;o Paulo Research Foundation-FAPESP, Takeda, and Wellcome Trust [106169/ZZ14/Z].</p></sec></ack></back></article>